tradingkey.logo

Precigen Inc

PGEN
4.290USD
+0.050+1.18%
終値 02/06, 16:00ET15分遅れの株価
1.52B時価総額
損失額直近12ヶ月PER

Precigen Inc

4.290
+0.050+1.18%

詳細情報 Precigen Inc 企業名

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Precigen Incの企業情報

企業コードPGEN
会社名Precigen Inc
上場日Aug 08, 2013
最高経営責任者「CEO」Sabzevari (Helen)
従業員数143
証券種類Ordinary Share
決算期末Aug 08
本社所在地20374 Seneca Meadows Parkway
都市GERMANTOWN
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号20876
電話番号13015569900
ウェブサイトhttps://precigen.com/
企業コードPGEN
上場日Aug 08, 2013
最高経営責任者「CEO」Sabzevari (Helen)

Precigen Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.32M
+557913.00%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.15M
+123618.00%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.14M
+116147.00%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
595.77K
+123331.00%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
579.24K
+123618.00%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
217.84K
+15000.00%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
110.60K
-235467.00%
Mr. Phil Tennant
Mr. Phil Tennant
Chief Commercial Officer
Chief Commercial Officer
65.03K
+6000.00%
Mr. Randal Joe Kirk
Mr. Randal Joe Kirk
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Donald P. Lehr
Mr. Donald P. Lehr
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.32M
+557913.00%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.15M
+123618.00%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.14M
+116147.00%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
595.77K
+123331.00%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
579.24K
+123618.00%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
217.84K
+15000.00%

収益内訳

通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
事業別USD
会社名
収益
比率
Collaborationandlicensingagreements
1.82M
62.22%
Service
942.00K
32.24%
Product
162.00K
5.54%
会社から関連データがまだ開示されていません。
事業別
地域別
事業別USD
会社名
収益
比率
Collaborationandlicensingagreements
1.82M
62.22%
Service
942.00K
32.24%
Product
162.00K
5.54%

株主

更新時刻: Mon, Nov 17
更新時刻: Mon, Nov 17
株主統計
種類
株主統計
株主統計
比率
Third Security, LLC
35.03%
Patient Capital Management, LLC
7.48%
Merck Serono SA
5.84%
Point72 Asset Management, L.P.
5.17%
William H. Miller III Living Trust
4.91%
他の
41.57%
株主統計
株主統計
比率
Third Security, LLC
35.03%
Patient Capital Management, LLC
7.48%
Merck Serono SA
5.84%
Point72 Asset Management, L.P.
5.17%
William H. Miller III Living Trust
4.91%
他の
41.57%
種類
株主統計
比率
Venture Capital
35.04%
Investment Advisor
16.54%
Hedge Fund
12.13%
Individual Investor
7.79%
Investment Advisor/Hedge Fund
6.56%
Corporation
5.84%
Research Firm
1.50%
Pension Fund
0.11%
Bank and Trust
0.07%
他の
14.44%

機関投資家保有株

更新時刻: Thu, Jan 1
更新時刻: Thu, Jan 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
319
238.99M
67.55%
+20.23M
2025Q3
286
222.21M
62.96%
+17.23M
2025Q2
298
229.52M
77.76%
-784.34K
2025Q1
334
228.75M
77.50%
-12.95M
2024Q4
336
223.34M
76.44%
-15.36M
2024Q3
342
222.44M
77.88%
+21.14M
2024Q2
350
183.56M
71.33%
-22.34M
2024Q1
356
187.95M
73.95%
-17.15M
2023Q4
369
187.18M
73.43%
-12.81M
2023Q3
377
185.65M
75.06%
-11.67M
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
Third Security, LLC
123.95M
35.03%
-4.78M
-3.71%
Nov 21, 2025
Patient Capital Management, LLC
26.46M
7.48%
+10.19M
+62.65%
Sep 30, 2025
Merck Serono SA
20.65M
5.84%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
2.74M
0.77%
+2.74M
--
Sep 30, 2025
William H. Miller III Living Trust
17.39M
4.91%
+17.39M
--
Jun 26, 2025
Tang Capital Management, LLC
12.40M
3.5%
+12.40M
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
10.74M
3.03%
+905.62K
+9.21%
Sep 30, 2025
The Vanguard Group, Inc.
8.94M
2.53%
-127.74K
-1.41%
Sep 30, 2025
State Street Investment Management (US)
4.49M
1.27%
+1.46M
+48.22%
Sep 30, 2025
Geode Capital Management, L.L.C.
3.85M
1.09%
+99.56K
+2.66%
Sep 30, 2025
詳細を見る

関連ETF

更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Inspire Small/Mid Cap ESG ETF
0.24%
ProShares Ultra Nasdaq Biotechnology
0.14%
iShares Micro-Cap ETF
0.12%
Invesco Nasdaq Biotechnology ETF
0.12%
State Street SPDR S&P Biotech ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
Direxion Daily S&P Biotech Bull 3X Shares
0.06%
iShares Biotechnology ETF
0.05%
iShares Russell 2000 Growth ETF
0.03%
ProShares UltraPro Russell2000
0.02%
詳細を見る
Inspire Small/Mid Cap ESG ETF
比率0.24%
ProShares Ultra Nasdaq Biotechnology
比率0.14%
iShares Micro-Cap ETF
比率0.12%
Invesco Nasdaq Biotechnology ETF
比率0.12%
State Street SPDR S&P Biotech ETF
比率0.11%
Vanguard US Momentum Factor ETF
比率0.1%
Direxion Daily S&P Biotech Bull 3X Shares
比率0.06%
iShares Biotechnology ETF
比率0.05%
iShares Russell 2000 Growth ETF
比率0.03%
ProShares UltraPro Russell2000
比率0.02%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
KeyAI